Physician
Endocrinology
Herman Blomeier works in the field of Endocrinology. He researched medicine at Jefferson Medical College. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Herman Blomeier is also a published doctor. He has 3 paper published. The most recent paper is: Role of the mitogen-activated protein kinases in cytokine-mediated inhibition of insulin gene expression. Herman Blomeier, MD accepts Medicare.
Publications
Schools
Jefferson Medical College Of Thomas Jefferson University
Northwestern University
Conditions Treated
- Abnormal Thyroid
- Adrenal Incidentaloma
- Adrenal Insufficiency
- Calcium Metabolism Disorders
- View All
Doctors Specialties
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Amerihealth
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- CoreSource
- Coventry Health Care of Illinois PPO
- Health and Life PPO
- Platinum PPO
- Coventry Health Care of Missouri PPO
- First Health (Coventry Health Care) PPO
- Golden Rule
- HealthLink PPO
- Choice Care PPO
- Preferred PPO
- Medicaid
- Medicare MCR
- Meritain Health
- MultiPlan PPO
- PHCS Network PPO
- Tricare
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
McGaw Medical Center of Northwestern University
-
Jefferson Medical College
Drug Facts
NPI NUMBER |
|
1003011800 |
NPPES Provider LastName |
|
BLOMEIER |
NPPES Provider FirstName |
|
HERMAN |
NPPES Provider ZIPCode |
|
600771057 |
NPPES Provider State |
|
IL |
Specialty Description |
|
Endocrinology |
Total Claim Count |
|
1754.0 |
Distinct Opioid Count |
|
0.0 |
Opioid Claim Count |
|
0.0 |
Percent Opioid Claims |
|
0.0 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
National Provider Identifier [NPI] |
1003011800 |
Last Name Of The Provider |
BLOMEIER |
First Name Of The Provider |
HERMAN |
View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog